A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
Completed · Phase 3 · NCT03524092
Conditions: Ulcerative Colitis
At a glance
- Research payments reported, 2025
- $1,800
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 1,328
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Mirikizumab SC (drug), Mirikizumab IV (drug), Placebo SC (drug)
- Dates
- Started 2018-10-19; completion 2025-02-17
- Results posted
- Yes
The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).
From ClinicalTrials.gov, last updated 2026-05-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1,800 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $1,800
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.